Insight Molecular Diagnostics Inc. Common Stock
Veridion Score
Composite trend over time
Why is IMDX moving today?
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for IMDX.
IMDX insider activity
Insight Molecular Diagnostics Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $5.3M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-06 | 2026-07-01 | Last Andrew J. | Insider | sell | $5.69 | 7,700 | 58,752 | $44K | SEC Form 4 |
| 2026-07-06 | 2026-07-01 | Arno Andrew | Insider | sell | $5.69 | 12,100 | 156,785 | $69K | SEC Form 4 |
| 2026-07-06 | 2026-07-01 | SILVERMAN LOU | Insider | sell | $5.69 | 7,700 | 55,807 | $44K | SEC Form 4 |
| 2026-04-27 | 2026-04-27 | BROADWOOD PARTNERS, L.P. | Insider | buy | $3.64 | 250,923 | 12,684,884 | $913K | SEC Form 4 |
| 2026-04-27 | 2026-04-24 | BROADWOOD PARTNERS, L.P. | Insider | buy | $3.53 | 38,880 | 12,433,961 | $137K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 9 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moIMDX contract awards, year to date.
Public federal awards linked to this ticker.
IMDX lobbying filings, year to date.
Registered lobbying filings matched to Insight Molecular Diagnostics Inc. Common Stock.